Form 4: ADC Therapeutics Director Jean-Pierre Bizzari Receives Annual Equity Grant

ADC Therapeutics SA Director Jean-Pierre Bizzari was granted 40,000 restricted stock units as part of his annual compensation, increasing his beneficial ownership to 119,502 common shares.

Summary

• Jean-Pierre Bizzari, a Director of ADC Therapeutics SA (ADCT), acquired 40,000 common shares.
• These shares were granted as Restricted Stock Units (RSUs) under the company's 2019 Equity Incentive Plan for his service as a Director.
• The RSUs were granted on June 3, 2025, at a price of $0, indicating a compensation grant rather than a purchase.
• The RSUs will vest one year from the grant date, contingent on Mr. Bizzari's continued service to the company.
• Following this transaction, Mr. Bizzari's total beneficial ownership in ADC Therapeutics SA stands at 119,502 common shares.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event of director compensation through equity, aligning interests. No negative implications are present, and it reflects standard corporate governance.

Positives

• The grant of RSUs aligns the director's interests with long-term shareholder value, as vesting is contingent on continued service.
• It represents a standard form of non-cash compensation for board members, indicating ongoing commitment from the director.

Risks

• The vesting of the 40,000 RSUs is subject to the reporting person's continued service to the Issuer, meaning the shares are not immediately owned and could be forfeited if service ceases before the one-year vesting period.

Future Outlook

The 40,000 Restricted Stock Units granted to Director Jean-Pierre Bizzari are scheduled to vest one year from the grant date (June 3, 2025), contingent on his continued service to the company. This will result in an increase in his direct share ownership upon vesting.

Industry Context

This filing details a routine insider transaction, specifically an equity compensation grant to a director. Such grants are a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to align the interests of board members with long-term shareholder value. It does not reflect broader industry trends but rather standard corporate governance and compensation practices.

Comparison to Industry Standards

• Director equity grants, such as Restricted Stock Units (RSUs), are a standard component of compensation packages for board members in the biotechnology and pharmaceutical industries, aligning director incentives with shareholder interests.
• While the specific value and vesting schedule of this grant would typically be benchmarked against peer companies like Moderna, BioNTech, or other clinical-stage biotech firms, this filing does not provide the necessary data for a direct comparative assessment of the grant's size relative to industry averages.

Corporate Governance

Related Party Transactions

• Grant of 40,000 Restricted Stock Units (RSUs) to Jean-Pierre Bizzari, a Director, as part of his annual compensation under the company's 2019 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders by tying compensation to future company performance and continued service. It also represents a potential future dilution upon vesting, which is a common aspect of equity compensation plans.
• Employees: No direct impact on employees is mentioned in this specific filing.

Next Steps

• Vesting of the 40,000 RSUs on June 3, 2026, subject to Jean-Pierre Bizzari's continued service to ADC Therapeutics SA.

Key Dates

Recommendation

Keywords

ADC Therapeutics, ADCT, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Beneficial Ownership